THOR - Synthorx, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
16.54
+0.14 (+0.85%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close16.40
Open16.36
Bid16.56 x 800
Ask16.99 x 1300
Day's Range16.00 - 16.82
52 Week Range11.00 - 23.53
Volume58,444
Avg. Volume74,174
Market Cap531.632M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire2 months ago

    Synthorx to Present at Jefferies 2019 Healthcare Conference

    SAN DIEGO, May 29, 2019 -- Synthorx, Inc. (NASDAQ: THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and.

  • GlobeNewswire2 months ago

    Synthorx to Present at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

    SAN DIEGO, May 15, 2019 -- Synthorx, Inc. (NASDAQ: THOR), a biotechnology company discovering and developing optimized biologics for cancer and autoimmune disorders, today.

  • GlobeNewswire3 months ago

    Synthorx Reports First Quarter Financial Results

    SAN DIEGO, April 30, 2019 -- Synthorx, Inc. (Nasdaq: THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and.

  • GlobeNewswire4 months ago

    Synthorx to Present at H.C. Wainwright Global Life Sciences Conference in London

    Synthorx, Inc. (THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced that management will present at the H.C. Wainwright Global Life Sciences Conference held in London, UK. Synthorx, Inc. is a biotechnology company focused on prolonging and improving the lives of people with cancer and autoimmune disorders. Synthorx’s proprietary, first-of-its-kind Expanded Genetic Alphabet platform technology expands the genetic code by adding a new DNA base pair and is designed to create optimized biologics, referred to as Synthorins.

  • GlobeNewswire4 months ago

    Synthorx to Present at the American Association of Cancer Research (AACR) Annual Meeting 2019

    Synthorx, Inc. (THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced the details of a poster presentation to be held at the American Association for Cancer Research (AACR) Annual Meeting 2019, taking place in Atlanta, Georgia. A Synthorin is a protein optimized through incorporation of novel amino acids encoded by the new DNA base pair that enables site-specific modifications, which enhance the pharmacological properties of these therapeutics.

  • GlobeNewswire4 months ago

    Synthorx Reports Fourth Quarter and Full Year 2018 Financial Results

    Company Positioned for Upcoming 2019 Milestones After Successful IPO Raising $150.7 Million in Gross Proceeds Presented Preclinical Safety and Anti-Tumor Data on Lead Product.

  • GlobeNewswire4 months ago

    Synthorx to Present at the Chinese Society for Clinical Oncology Conference on Immunotherapy

    Synthorx, Inc. (THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced the details of an oral presentation to be held at the Chinese Society for Clinical Oncology (CSCO) Conference on Immunotherapy, endorsed by the American Association for Cancer Research (AACR), taking place in Shanghai, China.  The oral session will be held on March 22, 2019 from 15:30 China Standard Time.

  • GlobeNewswire5 months ago

    Synthorx to Present at the 8th Annual SVB Leerink Global Healthcare Conference

    SAN DIEGO, Feb. 21, 2019 -- Synthorx, Inc. (NASDAQ: THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and.

  • GlobeNewswire7 months ago

    Synthorx Appoints Andrew Powell, J.D., to its Board of Directors

    Synthorx, Inc. (THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced the appointment of Andrew Powell, J.D., to its board of directors. In addition, current board member Pratik Shah, Ph.D., has been appointed chairman of the board.

  • GlobeNewswire7 months ago

    Synthorx Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    Synthorx, Inc. (THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced the closing of its previously announced initial public offering of 13,699,636 shares of common stock, which includes the exercise in full of the underwriters’ option to purchase 1,786,909 additional shares of common stock, at a public offering price of $11.00 per share. Jefferies LLC, Leerink Partners LLC and Evercore ISI acted as joint book-running managers for the offering. H.C. Wainwright & Co., LLC acted as lead manager for the offering.

  • GlobeNewswire7 months ago

    Synthorx Announces Pricing of Initial Public Offering

    Synthorx, Inc. (THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced the pricing of its initial public offering of 11,912,727 shares of common stock at a public offering price of $11.00 per share.  Synthorx anticipates total gross proceeds of approximately $131 million, before deducting underwriting discounts and commissions and other offering expenses. All shares of common stock are being offered by Synthorx. In addition, Synthorx has granted the underwriters a 30-day option to purchase up to an additional 1,786,909 shares of common stock at the initial public offering price.